奥扎格雷钠联合依达拉奉治疗基底节区脑梗死的疗效观察

Efficacy observation of sodium ozagrel combined with edaravone in the treatment of cerebral infarction in basal ganglia region

目的 观察奥扎格雷钠联合依达拉奉治疗基底节区脑梗死的临床效果。方法 90例基底节区脑梗死患者,按照随机数字表法分为A组、B组及C组,各30例。A组给予奥扎格雷钠进行治疗,B组给予阿司匹林联合依达拉奉进行治疗, C组给予奥扎格雷钠联合依达拉奉进行治疗。比较两组临床疗效及不同时间美国国立卫生研究院卒中量表(NIHSS)评分、Barthel指数(BI)。结果 治疗14 d后,C组NIHSS评分(10.42±1.37)分低于A组的(11.81±1.52)分和B组的(11.98±.45)分,差异有统计学意义(P<0.05), A组NIHSS评分与B组比较差异无统计学意义(P>0.05);治疗14 d后,三组Barthel指数比较差异无统计学意义(P>0.05);出院90 d后, C组NIHSS评分(6.05±0.64)分低于A组的(8.97±1.09)分和B组的(8.35±1.37)分, Barthel指数(86.49±13.49)分高于A组的(76.18±12.37)分和B组的(69.65±11.07)分,差异有统计学意义(P<0.05);出院出院90 d后, A组NIHSS评分与B组比较差异无统计学意义(P>0.05), A组Barthel指数(76.18±12.37)分高于B组的(69.65±11.07)分,差异有统计学意义(P<0.05)。C组总有效率86.67%明显高于A组的56.67%和B组的63.33%,差异有统计学意义(P<0.05);A组总有效率与B组比较差异无统计学意义(P>0.05)。结论 对基底节区脑梗死患者应用奥扎格雷钠联合依达拉奉治疗,在合理应用抗血小板药物的同时早期使用神经保护剂,并重视院后抗血小板药物的合理使用,提高依从性,及时调整药物,能有效提高患者生活质量,改善预后。

Objective To observe the clinical effect of sodium ozagrel combined with edaravone in the treatment of cerebral infarction in basal ganglia region.Methods A total of 90 patients with cerebral infarction in basal ganglia region were randomly divided into group A,group B and group C,with 30 cases in each group.Group A was treated with sodium ozagrel,group B was treated with aspirin combined with edaravone,and group C was treated with sodium ozagrel combined with edaravone.The clinical efficacy,National Institutes of Health stroke scale(NIHSS)score and Barthel index(BI)at different time points were compared between the two groups.Results After 14 d of treatment,the NIHSS score(10.42±1.37)points of group C was lower than(11.81±1.52)points of group A and(11.98±.45)points of group B,and the differences were statistically significant(P<0.05).There was no statistically significant difference in NIHSS score between group A and group B(P>0.05).After 14 d of treatment,there was no statistically significant difference in Barthel index among the three groups(P>0.05).At 90 d after discharge,the NIHSS score(6.05±0.64)points of group C was lower than(8.97±1.09)points of group A and(8.35±1.37)points of group B;the Barthel index(86.49±13.49)points of group C was higher than(76.18±12.37)points of group A and(69.65±11.07)points of group B;all the difference was statistically significant(P<0.05).At 90 d after discharge,there was no statistically significant difference in the NIHSS score between group A and group B(P>0.05).The Barthel index(76.18±12.37)points of group A was higher than(69.65±11.07)points of group B,and the difference was statistically significant(P<0.05).The total effective rate of group C(86.67%)was significantly higher than that of group A(56.67%)and group B(63.33%),and the difference was statistically significant(P<0.05).There was no statistically significant difference in the total effective rate between group A and group B(P>0.05).Conclusion For patients with cerebral infarction in the basal ganglia region treated by sodium ozagrel combined with edaravone,early use of neuroprotective agents while rational use of antiplatelet drugs,paying attention to the rational use of antiplatelet drugs after discharge,improving compliance and timely adjustment of drugs can effectively improve the quality of life and prognosis of patients.